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Abstract 
Extracellular microvesicles (ExMVs) are part of the cell secretome, and evidence has accumulated for their involve-
ment in several biological processes. Fourteen years ago our team demonstrated for the first time that ExMVs carry 
functional RNA species and proteins from one cell to another, an observation that opened up the new research field 
of horizontal transfer of bioactive molecules in cell-to-cell communication. Moreover, the presence of mRNA, noncod-
ing RNA, and miRNA in ExMVs in blood and other biological fluids opened up the possibility of employing ExMVs as 
new detection markers for pathological processes, and ExMVs became a target for “liquid biopsy” approaches. While 
ExMV-derived mRNAs may be translated in target cells into appropriate proteins, miRNAs regulate expression of cor-
responding mRNA species, and both RNA-depended ExMV-mediated mechanisms lead to functional changes in the 
target cells. Following from this observation, several excellent papers have been published that confirm the existence 
of the horizontal transfer of RNA. Moreover, in addition to RNA, proteins, bioactive lipids, infectious particles and intact 
organelles such as mitochondria may follow a similar mechanism. In this review we will summarize the impressive 
progress in this field—14 years after initial report.
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Introduction
Both single-celled organisms (e.g., bacteria, protozoea) 
and cells that are part of multicellular organisms com-
municate with the environment and other cells by sev-
eral mechanisms. The best known and studied so far are 
ligand–receptor-based interactions that involve peptides, 
bioactive lipids, extracellular nucleotides, and the cor-
responding specific receptors on the cell surface or in 
the cell cytoplasm that bind these ligands. Interestingly, 
evidence has accumulated that the one of most devel-
opmentally early cell-to-cell communication mecha-
nism involves spherical membrane fragments shed from 
the cell surface or the endosomal compartment, which 
have been described collectively as microparticles, 
microvesicles, or exosomes [1–5]. This communication 
mechanism is preserved in all species, and small spheri-
cal membrane fragments are currently called extracel-
lular microvesicles (ExMVs), as recommended by the 
International Society for Extracellular Vesicles [2]. While 
larger ExMVs (~100  nm–1  μm in diameter) are shed 
from lipid raft-enriched cell surface membrane domains 
by blebbing and budding of the cell membrane, smaller 
ExMVs (~40–150  nm), also known as exosomes, are 
derived from the endosomal cell membrane compart-
ment and originate from multivesicular bodies (MVBs) 
or from the release of Golgi apparatus-derived vesicles in 
the process of exocytosis (Fig.  1) [1–6]. Whatever their 
source, ExMVs that are released from normal healthy 
cells should be distinguished from apoptotic bodies that 
originate in dying cells. It is important to keep in mind 
this difference, because some small apoptotic bodies 
could be co-isolated with ExMVs [2].
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The fact that ExMVS are present in biological flu-
ids or in conditioned media harvested from cells cul-
tured in  vitro has been known for many years, and it 
has been suggested step by step by some investigators 
that these small spherical membrane structures play an 
important role in several biological processes. For exam-
ple, peripheral blood platelet-derived ExMVs have been 
demonstrated to be involved in the coagulation process 
[7], mesenchymal stromal cell (MSC)-derived ExMVs 
in bone mineralization [8], and B cell-derived ExMVs in 
regulation of certain T cell-mediated immune responses 
[9]. Nevertheless, for many years there was skepticism 
about the role of these membrane fragments in regulat-
ing cells, and they were often dismissed as “cell debris” 
released from damaged cells. Thus, many of the biologi-
cal effects of ExMVs were considered to be artifacts, and 
it took some time to convince the scientific community 
that ExMVs may be released from normal healthy cells. 
Now it seems likely that the trafficking of ExMVs was one 
of the first cell-to-cell communication mechanisms that 
emerged during evolution and anticipated the develop-
ment of more specific ligand-receptor interactions [1–6].
Following on this concept, some papers have been pub-
lished showing that ExMVs act as signaling device and 
activate target cells by ligands expressed on the ExMV 
surface [10, 11] or by the transfer of membrane recep-
tors from one cell to another [12]. However, one of the 
major problems with moving this field forward has been 
the lack of established methods to isolate, measure the 
concentration of, and purify ExMVs from biological flu-
ids. Some of these problems remain today, and several 
approaches have been proposed to unify isolation and 
enumeration protocols [2].
The most likely explanation for the rapid development 
of ExMV research, which has been followed by an expo-
nential increase in the number of published papers in 
subsequent years, has been the demonstration that these 
small cellular membrane fragments transfer RNA species 
and several other biologically active molecules between 
cells and thus may induce functional changes in the tar-
get cells [13–15]. These observations became particularly 
important at the time of discovery of stem cell plasticity, 
when some of the markers derived from cells employed 
as therapeutics were detected in cells in the damaged 
tissues. Rather than as a fusion phenomenon, this phe-
notypic and functional modification of target cells in 
damaged organs could at least partially be explained 
by the transfer of bioactive molecules from the cells 
employed as therapeutics [1, 16]. Moreover, the fact that 
ExMVs often possess a unique molecular signature that 
depends on the cell of origin, providing a kind of “busi-
ness card” with which to identify these cells, has opened 
the door to exploring their application as diagnostic tools 
to identify pathologic changes in the body. Based on this 
approach, ExMVs emerged as important diagnostic tar-
gets in so-called “liquid biopsies” [17].
Fig. 1 Upon activation, every cell type secretes ExMVs. Larger ExMVs (microvesicles) are released from the cell surface by blebbing and budding of 
the cell membrane, Smaller ExMVs (exosomes) are initiated in endosomes as intraluminal vesicles in multivesicular bodies (MVBs) after endocytosis 
of pathogens or due to activation of cells by other stimuli, or are generated in the Golgi apparatus during secretion of cell-synthesized proteins
Page 3 of 8Ratajczak and Ratajczak  Clin Trans Med  (2016) 5:7 
Of note, recently other applications of ExMVs have 
been considered. For example, they can be loaded 
with bioactive compounds and drugs as physiological 
liposomes and used as vehicles for drug delivery [2, 18]. 
Second, they may be employed in producing anti-tumor 
vaccines as well as therapeutic agents for infectious dis-
eases and even protection from graft-versus-host dis-
ease (GvHD) [2, 19]. Finally, as discussed below, ExMVs 
are ideal therapeutics to treat tissue and organ injuries, 
and horizontal transfer of RNA and other molecules here 
plays an important role.
ExMVs as signaling devices and vehicles for transfer of cell 
membrane receptors between cells
The formation of ExMVs was initially described in reticu-
locytes, and proposed as a mechanism by which matur-
ing reticulocytes employ to shed unnecessary receptors 
from the cell surface [20]. This observation was followed 
by the detection of ExMVs released by peripheral blood 
platelets and other types of cells. In the case of cancer 
cells, it has been proposed that release of ExMVs allows 
these cells to shed excess cell membranes [21]. However, 
as of today, this latter explanation seems to be somewhat 
trivial.
ExMVs are detectable in all biological fluids, includ-
ing blood plasma, intercellular fluid, cerebrospinal fluid, 
urine, sperm, bile, synovial fluid, saliva, and breast milk, 
as well as malignant effusions and ascites [1–6]. They 
can be considered as physiological liposomes in which, 
in the case of ExMVs, a surface phospholipid layer sur-
rounds inner content composed of coding and non-cod-
ing RNAs, proteins (e.g., enzymes, signaling components, 
transcription factors), bioactive lipids (e.g., sphingosine-
1-phosphate, prostaglandins, leukotrienes), signaling 
nucleotides, and metabolites [1–6]. As mentioned above, 
large ExMVs may also transfer organelles such as mito-
chondria between cells [22]. Expressed on the surface 
of ExMVs are receptors, adhesion molecules, and target 
cell-stimulating ligands—all “hijacked” from parental 
EXMVs-producing cells. As mentioned above evidence 
has accumulated that ExMVs may, on the one hand, 
transfer receptors and cell surface markers between cells 
[12] and, on the other hand, act as signaling devices by 
stimulating target cells [10, 11]. These signaling proper-
ties and their potential role in cell-to-cell communica-
tion were identified almost at the beginning of ExMV 
research. To support this blood platelet-derived ExMVs 
were found able to activate endothelial cells [23], poly-
morphonuclear leukocytes [24], and several leukemic 
cell lines [11]. The same blood platelet-derived ExMVs 
also stimulated cytokine secretion and tissue factor (TF) 
expression in endothelial cells [25], inhibited apopto-
sis of polymorphonuclear leukocytes [26], and induced 
chemotaxis of leukemic cells [11]. In addition to platelets, 
ExMVs are released from normal as well as pathologi-
cally altered nucleated cells (e.g., tumor cells) to directly 
stimulate target cells, and several elegant studies have 
described these interactions [1–6]. The interaction of 
target cells with ExMVs may result in increasing prolif-
eration and the inhibition of apoptosis, but in some situ-
ations ExMVs may actually inhibit cell growth [27–29]. 
These direct stimulatory or inhibitory effects depend on 
the repertoire of signaling molecules expressed on the 
surface of ExMVs. In support of this notion, we found 
for example that ExMVs (i) chemoattract human leuke-
mia cells; (ii) increase their adhesion, proliferation, and 
survival; and (iii) activate various intracellular signaling 
cascades, including MAPK p42/44, PI3K–AKT, and JAK–
STAT [11]. As of today, the signaling role of ExMVs has 
been reviewed in several excellent and comprehensive 
review papers [2–6, 30–34].
Besides soluble components such as growth factors, 
cytokines, chemokines, bioactive lipids, and extracellular 
nucleotides, ExMVs are part of a broadly understood “cell 
secretome” that is released from cells into the microen-
vironment [16]. Currently, much painstaking work has 
been done to identify proteins, lipids, and RNA compo-
nents of ExMVs [2]. It is obvious that the composition of 
the molecular signature of ExMVs varies depending on 
(i) the cell type that releases these spherical membrane 
fragments, (ii) the cell cycle status, (iii) the cell activation 
state, and (iv) the physiological or pathological condi-
tions of the secretome-producing cell.
In addition to playing the role of signaling devices, 
ExMVs may fuse with cell membranes and thus trans-
fer receptors from the cells of origin to target cells. This 
has been demonstrated by the transfer of CD41 antigens 
from blood platelets to hematopoietic cells [12]. This may 
explain a high expression of CD41 antigen on surface of 
hematopoietic stem cells (HSCs) that are derived by leu-
cophoresis from mobilized peripheral blood. Namely, 
during leucophoresis procedure platelets become acti-
vated in plastic tubing and release CD41+ ExMVs that 
subsequently may fuse with membranes of HSCs and 
after fusion render them CD41+ [12]. To support this 
phenomenon transfer of CD41 and certain other plate-
let-derived receptors (CD61, CD62) to the surface of 
HSCs may facilitate their engraftment after transplan-
tation [12]. On the other hand, as unwanted effect out-
dated peripheral blood platelets may be highly enriched 
for ExMVs that transfer the same molecules (CD41, 
CD61, CD62), which are involved in platelet adhesion to 
endothelium, to tumor cells and thus make cancer cells 
“sticky” to endothelium and predispose them to metas-
tasis [35]. This is one of the reasons why outdated plate-
lets should not be infused into cancer patients. A similar 
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transfer of cell membrane receptors has been observed 
in many cases and in glioblastomas for example, ExMVs-
derived from glioma cells transfer the oncogenic recep-
tor EGFRvIII to neighboring cells and thus increase their 
transforming potential [36].
Transfer of HIV-entry receptors by ExMVs from mono-
cytes (e.g., CD4 or CCR5) or blood platelets (CXCR4) 
may render other CD4−CXCR4−CCR5− cells sensitive 
to HIV entry [37, 38]. Interestingly, another rare ExMV-
mediated possibility exists in HIV infection, as it has 
been demonstrated that HIV may be carried as cargo 
inside ExMVs and transmit HIV by ExMV fusion with 
uninfected target cells. This latter possibility of rare HIV 
transfer has been described by mythological analogy as a 
“Trojan horse effect” [39, 40]. A similar mechanism has 
been postulated for the spread of prion infection [41, 42].
It is also worthwhile to mention that the transfer of 
receptors by ExMVs released from mature hematopoi-
etic cells during cell processing may create a problem 
for cleanly isolating lineage-negative hematopoietic 
stem/progenitor cells (HSPCs) using their cell surface 
marker expression. Such a procedure during so-called 
lineage depletion may lead to the loss of the most primi-
tive HSPCs, which after fusion with lineage-positive 
hematopoietic cell-derived ExMVs are themselves falsely 
stained as lineage-positive cells [43]. Moreover, it has also 
been demonstrated that the removal of erythrocytes by 
cell lysis employing hypotonic solution may lead to gen-
eration of erythrocyte-derived ExMVs that highly express 
annexin V on their surface, which after transfer to target 
cells (e.g., HSPCs), marks them falsely as cells that have 
initiated apoptosis [44]. These two examples demonstrate 
how important is to consider that ExMVs released during 
cell purification may change cell surface phenotype.
Horizontal transfer of bioactive molecules between cells 
by ExMVs
In addition to the role of ExMVs in directly stimulating 
target cells and their role in transfer of cell surface recep-
tors and markers, horizontal transfer of bioactive mol-
ecule cargo present inside ExMVs is their most important 
biological effect. However, as is common in science, novel 
observations require time to be accepted by the scientific 
community. It took us almost 3 years to publish our origi-
nal work on horizontal transfer of functional mRNA and 
proteins between cells by ExMVs after our initial report 
presented at the American Society of Hematology Meet-
ing 2003 in San Diego [45]. Our original paper, which was 
rejected from some top journals due to disbelief in the 
results, was finally accepted for publication by one of the 
less-conservative journal and appeared online by the end of 
2005 [13] and as for today is cited several hundred times.
In this aforementioned paper we assumed that the 
maintenance of pluripotency and the undifferentiated 
propagation of embryonic stem cells (ESC) in in  vitro 
cultures both require tight cell-to-cell contacts and effec-
tive intercellular signaling, and we have hypothesized 
that ESC-derived ExMVs express stem cell-specific mol-
ecules that support self-renewal and expansion of normal 
adult stem cells [13]. We found that, in fact, ESC-derived 
ExMVs enhanced survival and improved expansion of 
murine HSPCs and upregulated the expression of early 
pluripotent stem cell (October 4, Nanog, and Rex-1) and 
early hematopoietic stem cell (Scl, HoxB4, and GATA 2) 
markers in these cells. Furthermore, molecular analysis 
revealed that ExMVs from ESCs express Wnt-3 protein 
and are selectively highly enriched in mRNAs for several 
pluripotent transcription factors compared with parental 
ESCs. What is even more important, as demonstrated in 
that work these mRNAs could be horizontally transferred 
to HSPCs and translated into the corresponding proteins 
[13]. This biological effect was inhibited after heat inac-
tivation or pretreatment with RNAse, indicating a major 
involvement of protein and mRNA components in the 
observed phenomena [13].
Following this report, other very elegant studies con-
firmed the presence of horizontal transfer of mRNA via 
ExMVs derived from models of glioblastoma [15], murine 
and human mast cells [14], lung cells [46], endothelial 
cells [47], and mesenchymal stem cells [48]. Specifically, 
glioblastoma-derived ExMVs were found to be enriched 
for mRNA, miRNA, and proangiopoietic proteins and, 
after horizontal transfer of these molecules, promoted 
angiogenesis in growing tumors and stimulated tumor 
cell proliferation [15]. In another elegant work, ExMVs 
were demonstrated by microarray analysis to contain 
mRNAs for 1300 genes, and after ExMV-mediated trans-
fer of murine mRNA to human cells, murine-derived 
proteins were found to be expressed in recipient human 
cells [14]. Similar results were obtained in another very 
elegant study performed by another group of investiga-
tors in which lung cell-derived ExMVs transferred trans-
lationally active mRNAs into human hematopoietic 
cells, which led to the expression of lung-specific pro-
teins in   these cells [46, 49]. Finally, the phenomenon of 
horizontal transfer of specific mRNA subsets carried by 
endothelial cell-derived ExMVs to human umbilical vein 
endothelial cells (HUVECs) has been convincingly shown 
in another elegant work [47]. This ExMV-mediated 
transfer promoted the induction of angiogenic poten-
tial in HUVECs in in vitro cultures. A similar effect has 
also been observed in  vivo in SCID mice when human 
mammary epithelial cells (HMECs) exposed to endothe-
lial cells-derived ExMVs were embedded in matrigel 
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implants and transplanted subcutaneously to these mice 
[47].
In the following years, as follow up the phenomenon of 
horizontal transfer of RNA was demonstrated for ExMVs 
derived from peripheral blood platelets, hematopoietic 
CD34+ cells [50, 51], and CD133+ cells [52]. It has also 
been shown that this novel mechanism occurs also for 
noncoding RNA and miRNA [5, 14, 49, 52]. Thus, ExMVs 
enriched in RNA species became a focus of interest in 
several biological processes related to tissue and organ 
regeneration and as a potential diagnostic tool to detect 
pathological RNA species in the abovementioned liquid 
biopsies performed on samples aspirated from biological 
fluids (e.g., from blood plasma, ascites, pleural effusion) 
[17].
Importantly, it has been demonstrated in several ele-
gant studies that ExMVs derived from cells employed 
in regenerative medicine in therapy (e.g., mesenchy-
mal stromal cells) may also transfer several mRNA and 
miRNA species in a horizontal manner [53]. After deliv-
ery to the target cells, these are translated into proteins 
or regulate the expression of genes that inhibit apoptosis 
and/or promote angiogenesis in damaged tissues, such as 
kidney, myocardium, or liver [2, 16].
So far, horizontal transfer of RNA by ExMVs has been 
demonstrated for many types of normal and transformed 
cells and is also reportedly not species specific. It may 
be particularly important in the cell-to-cell communica-
tion mechanism employed by stem cells, which lack gap 
junctions, in interacting with other cells in the microen-
vironment [1–6, 13, 54]. It would be worthwhile to better 
explore how this mechanism is involved in the crosstalk 
of stem cells with other cells that comprise their specific 
niches.
Interestingly, it has been recently reported that a novel 
type of intestinal cells, known as a telocyte, secretes 
ExMVs to exert its regulatory functions in the tissues 
[55]. Telocytes may affect the biology of several cell types, 
including differentiated somatic cells and tissue-residing 
stem cells [56]. Evidence has accumulated that ExMVs are 
mediators of several long-distance paracrine functions 
of the telocytes residing in adult organs. Further work is 
needed to elucidate how these interactions are regulated 
via paracrine telocyte-mediated signals, including the 
release of ExMVs. As reported, telocytes express several 
miRNAs with pro-angiopoietic potential (miR-126, miR-
130, let-7e, and miR-100), and their number increases in 
the myocardium after heart infarct [57]. Therefore, the 
potential horizontal transfer of these miRNA species to 
the damaged myocardium via ExMVsmost likely pro-
motes angiogenesis [58].
There are several other excellent examples of the role of 
ExMVs in horizontal transfer of RNA and other bioactive 
molecules, but, because of space limitations, they neces-
sarily exceed the scope of this review. We therefore apol-
ogize to the various authors for not discussing several of 
these examples.
Novel potential applications of ExMV‑based strategies 
by utilization of horizontal transfer of RNA and other 
molecules
As mentioned above, it has been very convincingly 
shown in seminal work that ExMVs derived from mes-
enchymal stromal cells exert similar biological effects in 
models of tissue and organ regeneration in vivo as intact 
mesenchymal cells [53, 59]. This important observation 
opened new possibilities for therapeutic application of 
ExMVs, and these seem to be promising candidates for 
therapy, as they avoid problems related to the appli-
cation of intact cells [2, 53, 59]. Thus, it is possible to 
modulate ExMV-producing cells to engineer modified 
ExMVs to employ them more efficiently for tissue and 
organ regeneration in  vivo based on their paracrine 
effects, including horizontal transfer of RNA molecules 
(Fig. 2).
For example, ExMVs could be isolated for potential 
applications in regenerative medicine from a large-scale 
ex vivo expansion of cultured cells, for example, mesen-
chymal stem cells, in an appropriate culturing system. 
Taking advantage of epigenetic memory in induced pluri-
potent stem cell (iPSC)-differentiated cells, one can also 
envision that, for example, ExMVs from iPSCs obtained 
from dermal fibroblasts or iPSCs differentiated into epi-
dermal cells would preferentially affect the regeneration 
of damaged skin (e.g., after burns) [16]. Similarly, ExMVs 
isolated from the supernatants of iPSCs derived directly 
from cardiac fibroblasts or differentiated toward cardio-
myocytes would have advantages in the regeneration of 
damaged myocardium. This strategy, which we proposed 
in the past [16], has been recently successfully employed 
and reported in a recent paper [60].
In addition, as shown in Fig. 2, ExMVs-generating cells 
could be genetically modified in order to produce cus-
tom-engineered ExMVs more suitable for therapy [16, 
61]. First, as depicted in Fig.  2a, if it would be possible 
to generate and subsequently expand ExMV-producing 
cells that lack genes encoding histocompatibility anti-
gens. This approach would minimize the possibility of 
cross-immunization with donor HLA antigens. Second, 
ExMVs-producing cell lines could be transduced with 
genes that overexpress on the cell surface (i) peptides 
that protect target cells in damaged organs from apopto-
sis and stimulate proliferation of the residual remaining 
cell population (e.g., stem cell factor or Notch ligands) 
or (ii) factors that effectively induce angiogenesis (e.g., 
VEGF, FGF-2, or SDF-1) (Fig. 2b). As a third possibility, 
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ExMVs-producing cell lines could be enriched for mRNA 
and regulatory miRNA species that, after horizontal 
transfer to the damaged tissues, promote regeneration 
by inhibiting apoptosis and promoting angiogenesis 
(Fig. 2c). For example, we speculate that ExMVs derived 
from producer cell lines cultured in hypoxic conditions 
would be enriched in mRNAs and miRNAs that promote 
angiogenesis. Finally, we envision that ExMVs-producing 
cell lines could be enriched for molecules that facilitate 
their tropism to the damaged organ and subsequently 
promote retention of ExMVs in the damaged tissues 
(Fig. 2d).
Fig. 2 Different possible approaches to generating more efficient pro-regenerative ExMVs. ExMVs could be harvested from large-scale in vitro 
cultures of producing cell lines—for example, mesenchymal stem cells or induced pluripotent stem cells. Such cell lines may be modified to obtain 
ExMVs that do not express HLA antigens (a), are enriched in growth factors, cytokines, chemokines and bioactive lipids that promote regeneration 
of damaged organs (b), are enriched in mRNA and regulatory miRNA facilitating regeneration of damaged tissues and/or promoting angiogenesis 
(c), or display on their surface molecules that direct them to, and cause them to be retained in, damaged tissues (d) (adapted from Ratajczak et al. 
[16])
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Conclusions
Solid evidence has accumulated that ExMVs can transfer 
mRNA, miRNA, and large non-coding RNA molecules 
in addition to proteins, bioactive lipids, metabolites, 
and signaling nucleotides between cells in a horizontal 
manner [13–15, 46, 48, 52, 62, 63]. This phenomenon is 
involved in several physiological (e.g., tissue and organ 
regeneration, angiogenesis) as well as pathological (e.g., 
cancerogenesis) processes. Further work is needed to 
better purify ExMVs, separate them from apoptotic bod-
ies, and identify the full pattern of bioactive molecules, 
including all RNA species, that are present in ExMVs 
derived from different cell types. It will be important to 
decipher the molecular signature of mRNAs in ExMVs 
circulating in normal blood in human individuals, 
depending on sex and age.
Also important, there are emerging possibilities for 
more efficiently utilizing ExMVs in tissue and organ 
regeneration by generating ExMVs enriched in bioactive 
molecules, including the optimal signature of mRNAs 
and miRNAs for inhibiting cell apoptosis and increas-
ing angiogenesis of damaged tissues [16, 61]. Finally, 
more work is needed to shed more light on the secretory 
mechanism involved in ExMVs release from cells and 
their shedding from the cell surface membranes. Also 
needed are more efficient large-scale ExMVs isolation 
and purification methods.
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